Company intelligence / Profile preview
Quoin Pharmaceuticals Ltd.
- Ownership
- Public · QNRX
- Development stage
- Other
Overview
Quoin's lead product QRX003 has shown positive results in pediatric Netherton Syndrome studies, with one patient showing transformational improvement after just two weeks of whole-body application, including clear visual evidence of skin healing and discontinuation of previously required medications. The company is targeting FDA approval for its lead asset in 2026.
- Therapeutic areas
- Rare DiseasesDermatologyCardiovascularRheumatology
- Modalities
- Topical formulationsNovel drug delivery systems
- Industry
- Biotech
Drug pipeline
11 assets10 more assets in the full pipeline.
Partnerships
Financials
- Market cap
- $7.7M
- Total revenue
- $0
- Enterprise value
- $-2.4M
Beyond the preview
Go deeper on Quoin Pharmaceuticals Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Quoin Pharmaceuticals Ltd..